Geron (GERN) Other Non-Current Assets (2010 - 2026)
Geron's (GERN) quarterly Other Non-Current Assets came in at $5.7 million in Q2 2026, up 80.94% year-over-year from $3.1 million in Q2 2025, and down 4.17% quarter-over-quarter from $5.9 million in Q1 2026.
Analysis
Geron (GERN) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Geron has disclosed Other Non-Current Assets across 14 years of filings, most recently posting $5.7 million for Q2 2026.
- In Q2 2026, Other Non-Current Assets rose 80.94% year-over-year to $5.7 million; the TTM figure through Jun 2026 stood at $5.7 million (up 80.94% YoY), while the FY2025 annual figure was $5.9 million, up 45.75% from the prior year.
- Other Non-Current Assets came in at $5.7 million for Q2 2026 at Geron, down from $5.9 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $6.3 million in Q1 2022 to a low of $2.7 million in Q3 2025.
- Average Other Non-Current Assets over 5 years is $4.9 million, with a median of $4.8 million recorded in 2023.
- Year-over-year, Other Non-Current Assets sank 45.95% in 2025 and soared 80.94% in 2026.
- Over 5 years, Other Non-Current Assets stood at $5.4 million in 2022, then slipped by 12.84% to $4.7 million in 2023, then fell by 13.16% to $4.1 million in 2024, then surged by 45.75% to $5.9 million in 2025, then dropped by 4.19% to $5.7 million in 2026.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $5.7 million in Q2 2026, $5.9 million in Q1 2026, and $5.9 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 12.98 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 4.75 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 2.31 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 124.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 618.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 831.80 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 29.59 Mn |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | 5.70 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.70 Mn |
| Mar 31, 2026 | 5.94 Mn |
| Dec 31, 2025 | 5.95 Mn |
| Sep 30, 2025 | 2.67 Mn |
| Jun 30, 2025 | 3.15 Mn |
| Mar 31, 2025 | 4.04 Mn |
| Dec 31, 2024 | 4.08 Mn |
| Sep 30, 2024 | 4.93 Mn |
| Jun 30, 2024 | 4.74 Mn |
| Mar 31, 2024 | 4.71 Mn |
| Dec 31, 2023 | 4.70 Mn |
| Sep 30, 2023 | 5.20 Mn |
| Jun 30, 2023 | 4.75 Mn |
| Mar 31, 2023 | 4.69 Mn |
| Dec 31, 2022 | 5.39 Mn |
| Sep 30, 2022 | 5.51 Mn |
| Jun 30, 2022 | 5.70 Mn |
| Mar 31, 2022 | 6.32 Mn |
| Dec 31, 2021 | 4.80 Mn |
| Sep 30, 2021 | 4.88 Mn |